- Males or females 2 years and older
- Has a clinical diagnosis of Atopic Dermatitis (AD) according to the criteria of
Hanifin and Rajka
- Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)
- Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1
- All female subjects of childbearing potential must use acceptable methods of
contraception from the Screening Visit continuously until 30 days after stopping study
drug
- As determined by the study doctor, a medical history that may interfere with study
objectives
- Unstable AD or any consistent requirement for high potency topical corticosteroids
- History of use of biologic therapy (including intravenous immunoglobulin)
- Recent or anticipated concomitant use of systemic or topical therapies that might
alter the course of AD
- Recent or current participation in another research study
- Females who are breastfeeding, pregnant, or with plans to get pregnant during the
participation in the study
- Participation in a previous AN2728 clinical trial